Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor by Alfonso López de Sá, Alfonso López de Sá, Alicia de Luna, Alicia de Luna, Mónica Antoñanzas, Mónica Antoñanzas, Vanesa García-Barberán, Fernando Moreno-Anton, Fernando Moreno-Anton, Jose A. García-Sáenz, Jose A. García-Sáenz

Get full text

Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study by Alicia Milagros de Luna Aguilar, Javier David Benitez Fuentes, Justo Ortega Anselmi, Jennifer Olalla Inoa, Paloma Flores Navarro, Alfonso Lopez de Sá, Jesus Fuentes Antras, Cristina Rodríguez Rey, Aída Ortega Candil, Fernando Moreno Antón, Jose Ángel García Sáenz

Get full text

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial by Javier Salvador Bofill, Fernando Moreno Anton, Cesar Augusto Rodriguez Sanchez, Elena Galve Calvo, Cristina Hernando Melia, Eva Maria Ciruelos Gil, Maria Vidal, Begoña Jiménez-Rodriguez, Luis De la Cruz Merino, Noelia Martínez Jañez, Rafael Villanueva Vazquez, Ruben de Toro Salas, Antonio Anton Torres, Isabel Manuela Alvarez Lopez, Joaquin Gavila Gregori, Vanesa Quiroga Garcia, Elena Vicente Rubio, Juan De la Haba-Rodriguez, Santiago Gonzalez-Santiago, Nieves Diaz Fernandez, Agusti Barnadas Molins, Blanca Cantos Sanchez de Ibargüen, Juan Ignacio Delgado Mingorance, Meritxell Bellet Ezquerra, Sonia de Casa, Asuncion Gimeno, Miguel Martin

Get full text